deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT01739309

Study of LY2835219 for Mantle Cell Lymphoma

Phase 2 Study of a CDK4/6 Inhibitor for Patients With Relapsed or Refractory Mantle Cell Lymphoma

Sponsor: Eli Lilly and Company

Conditions Mantle Cell Lymphoma
Interventions Abemaciclib
Updated 16 times since 2017 Last updated: Sep 1, 2023 Started: Mar 20, 2013 Primary completion: Sep 28, 2015 Completion: Sep 5, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01739309, this PHASE2 trial focuses on Mantle Cell Lymphoma and remains completed. Sponsored by Eli Lilly and Company, it has been updated 16 times since 2013, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshot~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Oct 2019 · 6 months · monthly snapshot~Oct 2019 – ~Feb 2020 · 4 months · monthly snapshot~Feb 2020 – ~Dec 2020 · 10 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~May 2022 · 12 months · monthly snapshot~May 2022 – ~Mar 2023 · 10 months · monthly snapshot~Mar 2023 – ~Oct 2023 · 7 months · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Oct 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Mar 2023 — Oct 2023 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 11 earlier versions

  1. May 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE2

  2. May 2021 — May 2022 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  5. Feb 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE2

  6. Oct 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE2

  7. Apr 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE2

  8. Mar 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE2

  9. Jun 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE2

  10. Feb 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  11. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Mar 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations